title: Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
abstract: A 64-year-old woman with a 30-year history of recurrent sellar masses presented with severe headache and rapidly progressive visual field loss in the left eye. She was diagnosed with an extraventricular neurocytoma, which was octreotide positive, and was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu [DOTA0,Tyr3]octreotate (DOTATATE). After 4 induction and 4 maintenance treatment cycles, her headaches resolved, her vision improved, and her sellar mass stabilized. The use of 177Lu DOTATATE PRRT in the management of extraventricular neurocytoma warrants further research.
authors.affiliation: From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.
authors.forename: William
authors.initials: W
authors.lastname: Makis
authors.forename: Karey
authors.initials: K
authors.lastname: McCann
authors.forename: Alexander J B
authors.initials: AJ
authors.lastname: McEwan
mesh_terms: D005260:Female; D006801:Humans; D008875:Middle Aged; D018306:Neurocytoma / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000378:metabolism
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; C447941:lutetium Lu 177 dotatate; D015282:Octreotide